Steve Cochrane

President & CEO, Lithium Chile Inc.

Lithium Chile Inc.

The Canadian deal-maker who proved a junior could de-risk a Triangle brine far enough to attract US$175 million, at a multi billion dollar valuation.

This year, Steve Cochrane is walking away from the position he had held for nine years. New ideas and new eyes, Cochrane said. The trigger was not a failed drill hole. It was Ottawa. The Government of Canada had ordered a formal review, under the Investment Canada Act, of China Union Holdings' planned US$175 million acquisition of Argentum Lithium S.A. - the subsidiary that holds Lithium Chile's flagship Salar de Arizaro project in Salta, Argentina.

The sequence is pure critical-minerals politics. A Calgary junior builds one of the last large undeveloped salars in the Lithium Triangle to resource, PEA and PFS. Shareholders approve a Chinese buyer at a premium to market. Then the Canadian state decides that a lithium brine in Argentina, owned by a TSX-V company, may touch national interest.

Mr. Cochrane's exit turns a deal story into a larger argument: who is allowed to finance and own the next wave of lithium tonnes when Western capitals talk friend-shoring while Chinese capital still writes the biggest cheques.

For NES readers, the resignation is not an ending. It is the moment a capital-markets operator who spent a career raising money for small-cap miners collides with the new geopolitics of the battery metal.

Steve Cochrane matters because he personifies the junior lithium dilemma. Lithium Chile under his watch assembled a large Chilean land package, advanced Arizaro to a multi-billion-dollar PFS valuation, secured a Special Lithium Operating Contract (CEOL) pathway in Chile's Coipasa basin, and nearly monetised the Argentine flagship to a Chinese buyer, only to watch Ottawa open a formal national-security-style review.

For an international energy and strategic-minerals audience, he is the Canadian deal-maker who proved a junior could de-risk a Triangle brine far enough to attract US$175 million of Chinese interest, and who then discovered that the same Western capital markets that cheer “secure supply” can still block the exit. Why care this month? Because the Arizaro review and Cochrane's departure crystallise the capital allocation question hanging over every non-Chinese lithium project: build it, sell it, or sit on it while policy catches up.